EspeRare Receives FDA Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

These results, demonstrating that this prenatal treatment has a profound and life-changing effect on these infants,werepublished in the New England Journal of Medicine 1 .